Publications
497 publications
- Date
- Relevance
-
Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
The National Health Care Institute has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the ...
-
Zinnige Zorg room for improvement report - Appropriate use of pharmaceutical products for patients with castration-refractory prostate cancer (CRPC)
Within the framework of the Zinnige Zorg Programme, Zorginstituut Nederland systematically assesses the Dutch minimal and ...
-
Zinnige Zorg room for improvement report - Appropriate post-treatment surveillance of women treated for breast cancer
Within the framework of the Zinnige Zorg Programme, the National Health Care Institute systematically assesses the Dutch minimal ...
-
Fingolimod (Gilenya®)
The National Health Care Institute has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the ...
-
Future scenarios about drug development and drug pricing
This report is the result of a consultative and deliberative process — initiated by the Belgian Healthcare Knowledge Centre (KCE) ...
-
Tranylcypromine (Tracydal®) in patients with a severe multi-resistant depressive disorder
The National Health Care Institute carried out a budget impact analysis for the medicine tranylcypromine (Tracydal®). They ...
-
Tolperison (Tolpermyo®)
The National Health Care Institute has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo®), whereby it ...
-
Brivaracetam (Briviact®)
The National Health Care Institute has approved a pharmacotherapeutic report for the medicine brivaracetam (Briviact®), whereby ...
-
Lumacaftor/ivacaftor (Orkambi®) by Cystic fibrosis
Based on the GVS criteria, lumacaftor/ivacaftor (Orkambi®) can not be replaced by another drug in the GVS. The assessment ...
-
Eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria
The National Health Care Institute has re-assessed the medicine eculizumab (Soliris®) for the treatment of patients with ...